Literature DB >> 24589165

A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.

David M Lang1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24589165     DOI: 10.1016/j.anai.2014.01.019

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  2 in total

Review 1.  Omalizumab: a review of its use in patients with chronic spontaneous urticaria.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

2.  Insights and advances in chronic urticaria: a Canadian perspective.

Authors:  Gordon Sussman; Jacques Hébert; Wayne Gulliver; Charles Lynde; Susan Waserman; Amin Kanani; Moshe Ben-Shoshan; Spencer Horemans; Carly Barron; Stephen Betschel; William H Yang; Jan Dutz; Neil Shear; Gina Lacuesta; Peter Vadas; Kenneth Kobayashi; Hermenio Lima; F Estelle R Simons
Journal:  Allergy Asthma Clin Immunol       Date:  2015-02-11       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.